Discovery of a Multifunctional Ligand for Pain ReliefTechnology #ua15-050
Questions about this technology? Ask a Technology Manager
This technology is the discovery of a potent ligand, AKG177, with a balanced agonist activity with the two opioid receptors and antagonist activity at the neurokinin 1 receptor. The N-terminus was modified with an amino acid at the address region, enhancing receptor activity while binding to neurokinin 1. The blocking of the neurokinin 1 receptor can manage opioid tolerance, but studies show effectiveness is still retained when compared to morphine.
Pain is mediated through receptors for opioid drugs. Neurokinin 1 is the receptor for substance P, which is responsible for escalating pain and an important factor in opioid-induced hyperalgesia. Hyperalgesia is the increased sensitivity of pain. Marketed as a novel drug for pain management or to interested drug companies
- The invention has an advantage over current opioids by avoiding tolerance and opioid-induced hyperalgesia.
- Techniques and certain modifications may be useful to drug companies in order to improve tolerance for their existing opioid products.
- Pharmaceutical companies looking to improve the side effects of their existing opioids.